Xanthine derivatives
    1.
    发明公开
    Xanthine derivatives 失效
    叶黄素衍。

    公开(公告)号:EP0619316A1

    公开(公告)日:1994-10-12

    申请号:EP94105380.3

    申请日:1994-04-07

    IPC分类号: C07D473/04 A61K31/52

    CPC分类号: C07D473/04 Y10S514/869

    摘要: There is provided a novel xanthine Compound(I)

    wherein R¹ and R² are the same or different and each represent hydroxy-substituted, oxo-substituted or unsubstituted lower alkyl, Y is a single bond or alkylene, and Q is

    wherein R³ and R⁴ are the same or different and each represent hydrogen or hydroxy, n is 0 or 1; provided that when both of R³ and R⁴ are hydrogen, at least one of R¹ and R² is hydroxy-substituted or oxo-substituted lower alkyl; or a pharmaceutically acceptable salt thereof.
    The xanthine compound has adenosine A₁ receptor antagonizing activity, and thus shows diuretic effect, renal-protecting effect, bronchodilatory effect, cerebral function improving effect and anti-dementia effect.

    摘要翻译: 提供了一种新颖的黄嘌呤化合物(I)其中R 1和R 2相同或不同,各自表示羟基取代的,取代或未取代的低级烷基,Y是单键或亚烷基 且Q为,其中R 3和R 4相同或不同,各自表示氢或羟基,n为0或1; 条件是当R 3和R 4都是氢时,R 1和R 2中的至少一个是羟基取代的或氧代取代的低级烷基; 或其药学上可接受的盐。 黄嘌呤化合物具有腺苷A1受体拮抗活性,因此具有利尿作用,肾保护作用,支气管扩张作用,脑功能改善作用和抗痴呆作用。